Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Pfizer has entered into a licensing agreement worth up to $6 billion with Chinese biopharmaceutical firm 3SBio Inc, aiming to advance a promising cancer treatment currently in clinical trials. The collaboration underscores Pfizer’s growing interest in oncology and its strategic push into the Asian pharmaceutical market.
Under the agreement, 3SBio will take charge of developing, manufacturing, and commercializing the investigational drug in China. The compound, still in trial phases, is designed to treat various cancers and tumors, though specific indications have not been disclosed. Pfizer retains rights outside of China and will receive milestone payments and royalties based on development progress and commercial performance.
This partnership highlights a trend of Western pharmaceutical giants teaming up with Chinese biotech firms to accelerate access to cutting-edge therapies in one of the world’s fastest-growing healthcare markets. For Pfizer, the deal not only strengthens its oncology portfolio but also aligns with its broader strategy of expanding its presence in emerging markets.
The deal’s structure includes upfront and milestone payments that could total $6 billion, signaling strong confidence in the drug’s potential. It also reflects Pfizer’s continued investment in targeted cancer therapies and biologics, which have become critical areas of growth amid increasing global demand.
By collaborating with 3SBio, a company with established R&D and commercial infrastructure in China, Pfizer leverages local expertise to navigate regulatory pathways and bring advanced treatments to Chinese patients faster. For 3SBio, the partnership provides access to innovative science and strengthens its oncology pipeline.
This move is part of Pfizer’s ongoing strategy to forge global alliances that accelerate innovation and deliver next-generation cancer treatments worldwide. With the global oncology market projected to surpass $500 billion by 2030, such partnerships are key to staying competitive and impactful in the pharmaceutical space.
